CARLSBAD, Calif., April 01, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a

Related Keywords

University Of Washington , Washington , United States , American , Brianm Culley , Charlotte Hubbert , Corporate Development , University Of Washington Innovation Roundtable , Accelerator Corporation , Exchange Commission , Head Of Gates Foundation Venture Capital , Melinda Gates Foundation Strategic Investment Fund , Eterna Therapeutics Inc , Duke University , Roche Group , Vp Corporate Development , Genentech , Fred Hutch Cancer Institute Evergreen Fund , Institute For Stem Cells , Columbia University , Madrona Venture Group , Kauffman Society Of Fellows , Lineage Cell Therapeutics Inc , Lineage Cell Therapeutics , Vice President , Gates Foundation Venture Capital , Beckman Research Institute , Strategic Director , Madrona Venture , Sera Prognostics , Lodo Therapeutics , Agtech Accelerator , Vir Biotechnology , Harold Weintraub , Stem Cells , Regenerative Medicine , Kauffman Society , Fierce Woman , Life Science Washington , Fred Hutch Cancer Institute , Evergreen Fund , Washington Innovation Roundtable , Columbia University Lab To Market , Cell Therapeutics , Eterna Therapeutics , Annual Report ,